Good News for HER2 Positive MBC Patients!

Bestbird

If your cancer is HER2 positive and you've already had one or more HER2-directed therapies for metastatic disease, then you're eligible to receive the newly-approved combination of the oral drug Tukysa (Tucatinib) with Xeloda (capecitabine) and Herceptin (or an approved biosimilar).

FDA-approval for this combination was based upon the results of the HER2CLIMB study in which HER2 positive MBC patients, including patients with brain metastases (40% of which were untreated, or treated and progressing), were randomized to receive either the triplet of Tukysa (Tucatinib) in combination with Xeloda and Herceptin, or the doublet of Xeloda and Herceptin.The Overall Survival (OS) rate at 2 years was 44.9% for patients in the triplet arm vs. 26.6% in the doublet arm, and the median OS was 21.9 months vs. 17.4 months, respectively. Among patients with brain metastases, the Progression Free Survival (PFS) rate at 1 year was 24.9% in the triplet arm vs. 0% in the doublet arm, and the median PFS was 7.6 months vs. 5.4 months respectively. The overall and progression-free survival results were consistent across all prespecified subgroups based upon age, race, hormone receptor status, geographic location, and other factors. From: https://www.healio.com/hematology-oncology/breast-cancer/news/online/%7Be214fc90-55f9-43da-996c-adc16f7bae11%7D/fda-approves-tukysa-as-part-of-combination-therapy-for-breast-cancer

The above and similar information about approved MBC treatments and cutting edge research is in my book, "The Insider's Guide to Metastatic Breast Cancer" which is also available as a complimentary .pdf. For information, please visit https://www.insidersguidembc.com/about

cowgal

Thank you for the update! Always great to know there is something else when current treatments fail. I am Her2 Neu but it is always good to see something new for any of us stage 4 folks.

Bliss58

Yes, Bestbird, thank you for the update on this new HER2+ treatment.